Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325517 | 0.96 | MEN1 (0.48) | MEN1KMT2ALMNAPOLBCYP1A2 | |
| SCHEMBL1263510 | 0.96 | MEN1 (0.50) | MEN1KMT2ALMNAPOLBCYP1A2 | |
| SCHEMBL11537124 | 0.96 | MEN1 (0.50) | MEN1KMT2ALMNAPOLBCYP1A2 | |
| SCHEMBL25176578 | 0.91 | KMT2A (0.44) | MEN1KMT2ALMNAPOLBCYP1A2 | |
| SCHEMBL19104103 | 0.89 | MEN1 (0.44) | MEN1KMT2ALMNAPOLBEPHX2 | |
| SCHEMBL20547937 | 0.86 | KMT2A (0.41) | MEN1KMT2ALMNAPOLBCYP1A2 | |
| SCHEMBL20547938 | 0.86 | KMT2A (0.41) | MEN1KMT2ALMNAPOLBCYP1A2 | |
| SCHEMBL26695812 | 0.86 | EPHX2 (0.46) | MEN1KMT2ALMNAPOLBEPHX2 | |
| SCHEMBL22071027 | 0.86 | KMT2A (0.49) | MEN1KMT2ALMNAPOLB | |
| SCHEMBL2139571 | 0.86 | MEN1 (0.45) | MEN1KMT2ALMNAPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9493463-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9492457-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150322068-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9035050-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8987442-B2 | Deuterium-substituted xanthine derivatives and methods of use | CONCERT PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8952016-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140121226-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20110059995-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2011-03-10 | — | — | US | disclosed |
| US-20090239886-A1 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108375-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108383-A2 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322068-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | MEN1 2509/4885KMT2A 3943/4885LMNA 2823/4885 |
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | MEN1 2509/4885KMT2A 3943/4885LMNA 2823/4885 |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | MEN1 2509/4885KMT2A 3943/4885LMNA 2823/4885 |
| US-20090239886-A1 | Substituted xanthine derivatives | XDH, HPRT1, CXCR3 | MEN1 2509/4885KMT2A 3943/4885LMNA 2823/4885 |
| US-20110059995-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | MEN1 2509/4885KMT2A 3943/4885LMNA 2823/4885 |
| US-20140121226-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, CXCR4, CXCR3 | MEN1 1658/4885KMT2A 4056/4885LMNA 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.